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Drug eluting stents, which are coated with a pharmacologi-
cal antiproliferative agent that aims to combat restenosis,
are now part of the therapeutic armamentarium in inter-
ventional cardiology. During recent months, doubts have
been raised about the safety of these devices. In an
attempt to clarify the situation and to provide clinical and
interventional cardiologists with guidelines for their use,
the Société Française de Cardiologie has deemed useful to
examine the most recently published data on this subject.
This document, drafted in October 2007 by a consensus of
experts, will obviously need to be revised as further clinical
data are produced in the coming months and years.
What can be considered proven
With regard to effectiveness: drug eluting stents reduce the
incidence of clinical restenosis (“TLR”) by 75% on average in
patients included in randomized studies [1, 2], and there
were no “Catch Up Phenomena” after 4 years of follow up
[3]. In routine clinical practice, the reduction in the TLR
ranges from 55 to 65% (the difference between randomized
controlled trials and “real world” studies can be explained
by the use of angiographic control in randomized studies,
which increases TLR by between 10 and 20% [4]. Subgroup
analysis in pivotal studies, and specific randomized studies
have shown that this difference in clinical efficacy is consi-
derable in certain subgroups of patients with a high risk of
restenosis: in diabetics [1, 2, 5], in the case of lesions that
are more than 15 mm long, in arteries with a diameter of
less than 3 mm [6], in the treatment of restenosis in a bare
metal stent [7], in the treatment of chronic (more than
1 month) total coronary occlusion (experts opinion). This
proof of the efficacy of active stents compared to bare
metal stents lies at the heart of the recommendations for
the use of coated stents published by the Haute Autorité de
Santé and by the Société Française de Cardiologie. 
Safety of use
.As shown in a meta-analysis by Kastrati [8] and more
recently in a meta analysis by Stettler [9] concerning
18,000 patients included in 38 randomized studies with a
follow up of 4 years, there are no significant differences
between drug-eluting and bare metal stents with regard
to overall or cardiovascular-related mortality either in
the acute phase or after 3 or 4 years..In these randomized studies, there was no difference
between the two stent types for the overall incidence of
in-stent thrombosis at 1 month and 3 years after implan-
tation..However, after one year, there was a slightly, though
significantly, greater incidence of “very late” thrombosis
in drug-eluting stents than in bare metal stents. This
increased incidence of thrombosis, using the protocol defi-
nitions for stent thrombosis, was found for both Sirolimus
and Paclitaxel-eluting stents at long-term follow-up in the
pivotal studies [8, 10]. However, when Academic Research
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Consortium criteria were used to define stent thrombosis,
the difference remained significant only for paclitaxel-
eluting stents beyond 30 days [10]. The latter criteria
include thromboses which occur at repeat interventions;
these sometimes use techniques such as endocoronary
brachytherapy, which by itself can cause thrombosis.
What is under discussion
In terms of safety: high risk patients 
and “off-label” indications
The use of drug-eluting stents in so-called “off-label” indica-
tions presents a higher risk of in-stent thrombosis or death
than does use in “on-label” indications [11, 12]. It must be
pointed out, however, that it is difficult to characterize “on-
” or “off-label” indications because they are based on regu-
lations, which vary considerably over time and across coun-
tries. It is thus extremely difficult to take account of the
results of studies based on such a classification. It seems pre-
ferable to consider either data from randomized studies and
possibly subgroups in these studies or data from consecutive
registries, taking into account specific sub-groups. 
Randomized studies (cf Supra) have reported a likely but
slight increase in the incidence of late thrombosis (more than
1 year) for drug eluting stents compared with bare metal
stents. In the real world, it is impossible to demonstrate this
as there are no appropriate control groups. In particular,
when only bare metal stents existed, studies of in-stent
thrombosis did not exceed one month [13]. The predictors of
acute or sub-acute in-stent thrombosis (<1 month) are
known: they are associated with either the difficulty of the
procedure, or errors in the management of antiplatelet the-
rapy, and there are no differences between drug-eluting or
bare metal stents in this regard. The predictors of late or
very late thrombosis with drug-eluting stents are also quite
well known [11, 14]: factors present at the time of implanta-
tion are highly calcified coronary lesions, diabetes notably
insulin-dependent diabetes, renal insufficiency, the length
of the implanted stent and the number of treated segments.
Patients with an accumulation of risk factors (for example a
diabetic patient with several diseased arteries) are at a signi-
ficantly higher risk of developing in-stent thrombosis [11]. 
It is still debatable whether in such patients the risks asso-
ciated with stenting are greater than those associated with
surgery. There have been no comparative randomized stu-
dies on this subject (two are in progress); only the ARTS II
study [15], which matched a group of patients treated with
drug-eluting stents with a “historical” group from the ARTS I
randomized study, which compared CABG with angioplasty
using bare metal stents. The study reported that in terms of
mortality and efficacy drug-eluting stents were comparable
to CABG in patients with multivessel disease. 
In terms of safety: management and duration 
of antiplatelet treatment after implantation
of a drug-eluting stent
“Premature” interruption of antiplatelet therapy is a strong
predictor of thrombosis with drug-eluting stents [13, 16]. In
the PREMIER registry, mortality was significantly increased in
the case of premature interruption of the treatment with
clopidogrel. This increased risk may be explained by the
delayed endothelialisation that occurs with drug-eluting
stents compared to bare metal stents [17]. This led the Ame-
rican Heart Association/American College of Cardiology and
the Food and Drug Administration to recommend that the
treatment be continued for 12 months provided there was no
high risk of bleeding with dual antiplatelet therapy [18, 19].
This recommendation is in keeping with the recommenda-
tions for the use of dual antiplatelet therapy in acute coro-
nary syndromes, whatever the management strategy
employed. Such patients account for almost half of those
treated by angioplasty [20]. The recommended duration of
dual antiplatelet treatment of at least one year after the
implantation of a drug-eluting stent is empiric and pragma-
tic. There have been no specific studies that deal with the
problem of stopping the treatment after one year, and
uncertainty about the optimal duration of dual antiplatelet
therapy remains. The results of the CHARISMA study [21],
involving 15 000 patients at a high risk for atherothrombosis
(but most of whom were not treated with either drug-eluting
or bare metal stents) are not in favor of prolonged dual anti-
platelet therapy beyond one year (the risk of hemorrhage
increases, with no improvement in efficacy); in this trial,
however, the excess risk of hemorrhage appeared mainly at
the beginning of dual therapy and after the first months of
treatment the risk was no higher than that found in patients
on aspirin alone [22]. In contrast, there have been a number
of isolated cases of very late in-stent thrombosis (up to
4 years after the implantation of a drug-eluting stent) at the
moment when antiplatelet therapy is interrupted, notably
prior to non-cardiac surgery; the incidence of late or very
late thrombosis is about 0.6%/year [23]. However, cases of
late thrombosis (>1 year) have also been reported in patients
still receiving dual anticoagulation therapy [24]. The stra-
tegy of long-term antiplatelet therapy and the possible role
of monitoring platelet function need to be investigated in
prospective studies. Currently, it is not possible to give a for-
mal recommendation to prolong or to avoid prolonging dual
antiplatelet therapy to beyond a year.
Sub groups
Diabetics
The risk of restenosis after implantation of a bare metal
stent and the benefits of drug-eluting stents, in terms of pre-
vention of restenosis, are both higher in diabetic than in non-
diabetic patients. The risk of thrombosis is also greater than
in non-diabetics [11]. According to a meta-analysis by Stett-
ler [9], mortality among diabetic patients during the first 4
years after the implantation of a drug eluting stent is slightly
higher, but the difference is not statistically significant (OR:
1.16 for paclitaxel stents, p =0.55; OR: 1.24 for sirolimus
stents, p=0.29, compared with bare metal stents). 
Acute ST-elevation myocardial infarction
Restenosis is less frequent following primary angioplasty for
acute MI than following angioplasty for other reasons [25,
26]. Implanting a drug-eluting stent to prevent restenosis
therefore seems to be less necessary in these circumstances
[27]. Randomized studies and registries have not revealed
any significant difference between drug-eluting stents and
bare metal stents for mortality at one-year. Beyond one
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year, as shown in data from the GRACE registry (Steg PG,
presentation during the European Society of Cardiology
congress 2007), a potentially increased risk among patients
with a drug-eluting stent cannot be excluded.
Moreover, since primary angioplasty is performed as an
emergency intervention, it is more difficult to evaluate at
the time of the intervention the medium and long-term risk
of bleeding and the ability of patients to comply with long
term dual antiplatelet therapy. All of the above suggest
that caution is required when considering the implantation
of a drug-eluting stent in this particular indication.
Left main coronary artery
Coronary artery surgery is the treatment of choice for ste-
nosis of the left main coronary artery [28]. Multicentre
registries show satisfactory clinical results with drug-elu-
ting stents during the first year [29, 30]. However, until the
results of ongoing randomized studies comparing drug-elu-
ting stents with surgery become available, the use of angio-
plasty must remain an exception, and assessed on a case-
by-case basis according to the clinical and anatomical con-
text of each patient, notably for patients with a very high
risk score for surgery (EUROSCORE or other). When angio-
plasty is chosen, drug-eluting stents seem to give better
results in the medium term compared to conventional
stents and thus seem to be preferable. As is the case for all
stents, the benefit/risk ratio for long-term dual antiplate-
let therapy has to be assessed.
The cost/benefit ratio for active stents
The absence of any improvement in mortality makes it
impossible to establish a cost/benefit ratio in terms of
increased life expectancy. The cost/benefit ratio is thus
calculated with regard to the marginal cost of avoiding
myocardial revascularisation, or to the resulting improve-
ment in quality of life. Depending on the way cost analysis
is modeled in such studies, the health costs in the different
countries and the acceptable marginal cost threshold to
avoid an adverse event, the use of a drug-eluting stent
seems to be cost-effective in the overall population of sten-
ted patients (SIRIUS medico-economic study, [31]), cost-
effective only in certain sub groups of patients (for example
in the BASKET study in patients with multivessel disease,
long lesions and narrow vessels, [32]) or not cost-effective
in most clinical situations (Nice 2007, [3]). There is still
great uncertainty on this issue.
Not all drug eluting stents are identical
In terms of efficacy, if we consider only drug-eluting stents
that are subject to reimbursement because they have been
shown beneficial in terms of prevention of restenosis compa-
red with bare metal stents, there are probable differences:
the intermediate angiographic criterion “late loss”, which
reflects the degree of secondary proliferation either inside
the stent or at the border, and which appears to correlate
strongly with the “TLR” [33] is greater for paclitaxel than for
sirolimus stents, significantly greater for the zotarolimus
(ENDEAVOR) than the sirolimus stent (ENDEAVOR III study
[34]), significantly lower for everolimus (Xience, promus)
stents than for paclitaxel stents (Spirit II and III studies [35]).
These results are contested by some, notably because the
difference between sirolimus and paclitaxel stents in the
REALITY study [36] with regard to binary restenosis was not
significant. However, with regard to the “TLR” the sirolimus
stent was more effective than the paclitaxel stent [8], ten-
ded to be more effective than the zotarolimus stent [34],
and again with regard to the TLR the everolimus stent was
more effective than the paclitaxel stent. Finally, the results
presented to the TCT 2007 congress on the direct comparison
between zotarolimus and paclitaxel stents showed that the
paclitaxel stent was no better than the zotarolimus stent in
terms of “target vessel failure” and “TLR”.
In terms of safety, because of the low power of the stu-
dies and the insufficient follow-up it is impossible to con-
firm or deny that an active stent is safer than another in
terms of the risk of in-stent thrombosis.
General guidelines
Though drug-eluting stents are undoubtedly effective to
reduce the risk of restenosis, real doubts persist regarding
the risk of late thrombosis and the optimal duration of dual
antiplatelet treatment. Because of these doubts, it is neces-
sary to weigh the benefits against the risks for every patient
particularly carefully. The estimated risk of restenosis, the
long-term risk of hemorrhage and the ability of the patient to
comply with protracted antiplatelet therapy meticulously
must all be taken into account. By the same token, it is essen-
tial to check whether the patient is likely to undergo surgery
(cardiovascular or general) in the year following stent implan-
tation. It is also advisable to assess the risk of emergency sur-
gery according to the status of the patient (the annual inci-
dence of a surgical intervention among the elderly is high,
while the risk of trauma-related surgery should be taken into
account for certain populations at risk). The recommenda-
tions issued by Learned Societies [37] and health authorities,
which are regularly updated to keep in step with studies that
show the safety and efficacy of a new indication, must be the
reference for everyday clinical practice. Moreover, it is
essential that hospital records and discharge letters specifi-
cally mention the precise description of stent used and its
type (drug-eluting or bare metal) as well as the need for com-
bined antiplatelet therapy for at least one year, which is in
keeping with the current consensus. However, in the absence
of any formal scientific facts about the optimal duration of
dual antiplatelet therapy, it may be reasonable to propose a
shorter course of treatment (6 months) in certain specific ins-
tances, after a careful and justified assessment of the bene-
fit/risk ratio on a case-by-case basis. Likewise, whether dual
antiplatelet therapy should be continued for longer than a
year must be considered for each patient. Until more precise
data become available, treatment could be prolonged in
patients with particular risk factors for thrombosis, or those
in whom the onset of acute thrombosis would lead to a parti-
cularly high clinical risk (stenosis of the proximal left anterior
descending artery, for example), if there is no increased risk
of hemorrhage. Patients with particular risks should be issued
with cards carrying this information. Finally, it must be
explained to patients who have received a drug-eluting stent
that antiplatelet therapy must under no circumstances be
stopped without the prior agreement of a cardiologist. All of
the above implies that a structured comprehensive discussion
must take place between the patient and the interventional
cardiologist: in every case, the cardiologist must bear in mind
that he or she is treating a patient, and not just his/her coro-
nary arteries. 
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